FDA Grants Approval for Metformin Hydrochloride ANDA077060 by Zydus Lifesciences
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride submitted by Zydus Lifesciences.
Asset / Drug
Drug and asset intelligence for Metformin with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
A multicenter trial will evaluate the efficacy of metformin in improving cardiac function in LVAD patients over 12 months.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.